Podcast

The Future Of iPSCs With BlueRock Therapeutics' CEO Seth Ettenberg

Source: Applied Biosystems by Thermo Fisher Scientific, qPCR
22_01_CGPodcast_1200x628_Ep38

BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.

          

 

access the Podcast!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

Applied Biosystems by Thermo Fisher Scientific, qPCR